Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

Summary

Participants will undertake a 12-week, open-label study of milnacipran in a well-characterized cohort of patients with fibromyalgia syndrome (FMS) who are 65 years and older to investigate the short-term efficacy and safety of this drug in the elderly population. The investigators hypothesize that milnacipran will be effective in treating fibromyalgia syndrome (FMS), and will be prove to be safe when patients are selected for the absence of pre-existing blood pressure abnormalities and other serious medical conditions.

Timeline

Start

2011-03

Primary completion

2011-08

Completion

2011-08

Drugs

Indications